Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity

Molecular Cancer Therapeutics

Volumn 2, Issue 10, 2003, Pages 995-1002

  Disis, Mary L ^a   Scholler, Nathalie ^b   Dahlin, Amber ^b   Pullman, Janice ^b   Knutson, Keith L ^a   Hellstrom̈, Karl Erik ^b   Hellstrom̈, Ingegerd ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD137 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; CD86 PROTEIN, RAT; COMPLEMENTARY DNA; DNA; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LEUKOCYTE ANTIGEN; LIGAND; MEMBRANE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TNFRSF9 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR; TYROSINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MOUSE; NEOPLASM; PHOSPHORYLATION; PLASMID; RAT; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD80; ANTIGENS, CD86; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; DNA; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; LIGANDS; LYMPH NODES; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHOSPHORYLATION; PLASMIDS; PROTEIN-TYROSINE KINASES; RATS; RECEPTOR, ERBB-2; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; TYROSINE; VACCINES, DNA;

EID: 2442704168     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. A. DNA vaccines. Rev. Immunol., 15: 617-648, 1997. (Pubitemid 27169294)
2. Disis, M. L. Immunologic targets for breast cancer therapy. Breast Disease, 15: 83-90, 2003.
3. Gurunathan, S., Klinman, D. M., and Seder, R. A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol., 18: 927-974, 2000. (Pubitemid 30365401)
4. Nakamura, K., Saitoh, A., Yasaka, N., Furue, M., and Tamaki, K. Molecular mechanisms involved in the migration of epidermal dendritic cells in the skin. J. Invest. Dermatol. Symp. Proc., 4: 169-172, 1999. (Pubitemid 29489043)
5. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319: 226-230, 1986. (Pubitemid 16128785)
6. Jallal, B., Schlessinger, J., and Ullrich, A. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells. J. Biol. Chem., 267: 4357-4363, 1992.
7. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.
8. Disis, M. and Cheever, M. HER-2/neu protein: a target for antigen specific immunotherapy of human cancer. In: G. V. Woude and G. Klein (eds.). Adv. Cancer Res. Vol. 71, pp. 343-371. San Diego: Academic Press, 1997.
9. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244: 707-712, 1989. (Pubitemid 19147683)
10. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992.
11. Reilly, R. T., Machiels, J. P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D., and Jaffee, E. M. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res., 61: 880-883, 2001. (Pubitemid 32174395)
12. Cannons, J. L., Lau, P., Ghumman, B., DeBenedette, M. A., Yagita, H., Okumura, K., and Watts, T. H. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol., 167: 1313-1324, 2001. (Pubitemid 32703127)
13. Blazar, B. R., Kwon, B. S., Panoskaltsis-Mortari, A., Kwak, K. B., Peschon, J. J., and Taylor, P. A. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol., 166: 3174-3183, 2001. (Pubitemid 33117315)
14. Gramaglia, I., Cooper, D., Miner, K.T., Kwon, B. S., and Croft, M. Costimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur. J. Immunol., 30: 392-402, 2000. (Pubitemid 30098831)
15. Mittler, R. S., Bailey, T. S., Klussman, K., Trailsmith, M. D., and Hoffmann, M. K. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med., 190: 1535-1540, 1999.
16. DeBenedette, M. A., Shahinian, A., Mak, T. W., and Watts, T. H. Costimulation of CD28-T lymphocytes by 4-1BB ligand. J. Immunol., 158: 551-559, 1997. (Pubitemid 127492629)
17. Melero, I., Bach, N., Hellstrom, K. E., Aruffo, A., Mittler, R. S., and Chen, L. Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol., 28: 1116-1121, 1998. (Pubitemid 28116225)
18. Chapman, B. S., Thayer, R. M., Vincent, K. A., and Haigwood, N. L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res., 19: 3979-3986, 1991. (Pubitemid 21912770)
19. Jang, S. K. and Wimmer, E. Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein. Genes Dev., 4: 1560-1572, 1990.
20. Freeman, G. J., Gray, G. S., Gimmi, C. D., Lombard, D. B., Zhou, L. J., White, M., Fingeroth, J. D., Gribben, J. G., and Nadler, L. M. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med., 174: 625-631, 1991.
21. Borriello, F., Oliveros, J., Freeman, G. J., Nadler, L. M., and Sharpe, A. H. Differential expression of alternate mB7-2 transcripts. J. Immunol., 155: 5490-5497, 1995.
22. Hillova, J., Hill, M., Goubin, G., and Dantchev, D. Infectivity of Rous sarcoma cell DNA: comparison of two techniques of transfection assay. Intervirology, 5: 367-374, 1975.
23. Miller, A. D. and Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-990, 1989. (Pubitemid 19262578)
24. Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., and Cheever, M. A. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J. Immunol., 156: 3151-3158, 1996.
25. Rapaport, E., Fishman, R. F., and Gercel, C. Growth inhibition of human tumor cells in soft-agar cultures by treatment with low levels of adenosine 5′-triphosphate. Cancer Res., 43: 4402-4406, 1983. (Pubitemid 13041879)
26. Reese, D. M. and Slamon, D. J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells, 15: 1-8, 1997. (Pubitemid 27057075)
27. Connelly, P. A. and Stern, D. F. The epidermal growth factor receptor and the product of the neu proto-oncogene are members of a receptor tyrosine phosphorylation cascade. Proc. Natl. Acad. Sci. USA, 87: 6054-6057, 1990.
28. Nanda, N. K. and Sercarz, E. E. Induction of anti-self-immunity to cure cancer. Cell, 82: 13-17, 1995.
29. Moudgil, K. D. and Sercarz, E. E. The self-directed T cell repertoire: its creation and activation. Rev. Immunogenet., 2: 26-37, 2000. (Pubitemid 30142481)
30. Perales, M. A., Blachere, N. E., Engelhorn, M. E., Ferrone, C. R., Gold, J. S., Gregor, P. D., Noffz, G., Wolchok, J. D., and Houghton, A. N. Strategies to overcome immune ignorance and tolerance. Semin. Cancer Biol., 12: 63-71, 2002. (Pubitemid 34087900)
31. Kelsall, B. L., Biron, C. A., Sharma, O., and Kaye, P. M. Dendritic cells at the host-pathogen interface. Nat. Immunol., 3: 699-702, 2002.
32. Steinman, R. M. and Pope, M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest., 109: 1519-1526, 2002. (Pubitemid 34663511)
33. Mellman, I. and Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell, 106: 255-258, 2001. (Pubitemid 32772607)
34. Nestle, F. O., Banchereau, J., and Hart, D. Dendritic cells: on the move from bench to bedside. Nat. Med., 7: 761-765, 2001. (Pubitemid 32691622)
35. Reinhard, G., Marten, A., Kiske, S. M., Feil, F., Bieber, T., and Schmidt-Wolf, I. G. Generation of dendritic cell-based vaccines for cancer therapy. Br. J. Cancer, 86: 1529-1533, 2002. (Pubitemid 34628103)
36. Langstein, J. and Schwarz, H. Identification of CD137 as a potent monocyte survival factor. J. Leukoc. Biol., 65: 829-833, 1999. (Pubitemid 29279533)
37. Wen, T., Bukczynski, J., and Watts, T. H. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J. Immunol., 168: 4897-4906, 2002. (Pubitemid 34495951)
38. Miller, R. E., Jones, J., Le, T., Whitmore, J., Boiani, N., Gliniak, B., and Lynch, D.H.4-1BB-specificmonoclonal antibody promotes thegeneration of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol., 169: 1792-1800, 2002. (Pubitemid 34857639)
39. Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., and Chen, L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest., 109: 651-659, 2002. (Pubitemid 34204844)
40. Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S., and Chen, L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol., 190: 167-172, 1998. (Pubitemid 29011104)
41. Schwartz, J. C., Zhang, X., Nathenson, S. G., and Almo, S. C. Structural mechanisms of costimulation. Nat. Immunol., 3: 427-434, 2002. (Pubitemid 34520791)
42. Lenschow, D. J., Walunas, T. L., and Bluestone, J. A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol., 14: 233-258, 1996. (Pubitemid 26130184)
43. Guinn, B. A., DeBenedette, M. A., Watts, T. H., and Berinstein, N. L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol., 162: 5003-5010, 1999. (Pubitemid 29314909)
44. Maus, M. V., Thomas, A. K., Leonard, D. G., Allman, D., Addya, K., Schlienger, K., Riley, J. L., and June, C. H. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol., 20: 143-148, 2002. (Pubitemid 34158029)
45. Shawver, L. K., Mann, E., Elliger, S. S., Dugger, T. C., and Arteaga, C. L. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Cancer Res., 54: 1367-1373, 1994. (Pubitemid 24108083)
46. Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., and Sela, M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene, 14: 2099-2109, 1997. (Pubitemid 27237013)
47. Lee, K. H., Panelli, M. C., Kim, C. J., Riker, A. I., Bettinotti, M. P., Roden, M. M., Fetsch, P., Abati, A., Rosenberg, S. A., and Marincola, F. M. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol., 161: 4183-4194, 1998. (Pubitemid 28469000)
48. Martinet, O., Divino, C. M., Zang, Y., Gan, Y., Mandeli, J., Thung, S., Pan, P. Y., and Chen, S. H. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther., 9: 786-792, 2002. (Pubitemid 34679306)
49. Disis, M., Shiota, F., McNeel, D., and Knutson, K. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self-tumor antigens. Immunobiology, 207: 1-8, 2003.
50. Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., and Schiffman, K. Generation of T-cell immunity to the her-2/neu protein after active immunization with her-2/neu peptide-based vaccines. J. Clin. Oncol., 20: 2624-2632, 2002. (Pubitemid 34575634)
51. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., and Brugger, W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 96: 3102-3108, 2000.